EQS-News: Promotion for SCHOTT Pharma: Listed on the MDAX for the first time
|
EQS-News: SCHOTT Pharma AG & Co. KGaA
/ Key word(s): Miscellaneous
Promotion for SCHOTT Pharma: Listed on the MDAX for the first time
The shares of SCHOTT Pharma AG & Co. KGaA, a global market leader for drug containment solutions and delivery systems, will be included in the MDAX for the first time as of September 23, 2024. Andreas Reisse, CEO of SCHOTT Pharma, said: “We are delighted that less than one year after our IPO and nine months in the SDAX we are moving up to the next league. The MDAX entry is further proof of the continued confidence of our investors in our business model and our strategy. We look forward to building on this next milestone.”
As part of the 90 most important prime standard shares listed on the Frankfurt stock exchange, the MDAX index comprises the 50 largest and most liquid companies following the DAX in terms of market capitalization. SCHOTT Pharma (WKN A3ENQ5, ISIN DE000A3ENQ51) has been listed on the Frankfurt Stock Exchange since September 2023 and part of the SDAX since December 2023. Dr. Almuth Steinkühler, CFO of SCHOTT Pharma, said: “Today is yet another special day for SCHOTT Pharma. We are excited about joining the MDAX and further strengthening our position and visibility in the capital market. The promotion to the MDAX is proof of our strong financial performance and offers SCHOTT Pharma the best conditions to further achieve its ambitious growth targets.” The company announced its Q3 2024 results on August 29, 2024, and will publish its annual report for the fiscal year 2024 on December 12, 2024.
About SCHOTT Pharma Human health matters. That is why SCHOTT Pharma designs solutions grounded in science to ensure that medications are safe and easy to use for people around the world. The portfolio comprises drug containment solutions and delivery systems for injectable drugs ranging from prefillable glass and polymer syringes to cartridges, vials, and ampoules. Every day, a team of over 4,600 people from over 60 nations works at SCHOTT Pharma to contribute to global healthcare. The company is represented in all main pharmaceutical hubs with 16 manufacturing sites in Europe, North and South America, and Asia. With over 1,000 patents and technologies developed in-house and a state-of-the-art R&D center in Switzerland, the company is focused on developing innovations for the future. SCHOTT Pharma AG & Co. KGaA is headquartered in Mainz, Germany and listed on the Frankfurt Stock Exchange as part of the SDAX. It is part of SCHOTT AG, which is owned by the Carl Zeiss Foundation. In light of this spirit, SCHOTT Pharma is committed to sustainable development for society and the environment and has the strategic goal of becoming climate-neutral by 2030. Currently, SCHOTT Pharma has over 1,800 customers including the top 30 leading pharma manufacturers for injectable drugs and generated revenue of EUR 899 million in the fiscal year 2023.
Press contact: Lea Kaiser Tobias Erfurth Jasko Terzic, CFA Simon Steiner Christopher Raad
05.09.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
| Language: | English |
| Company: | SCHOTT Pharma AG & Co. KGaA |
| Hattenbergstraße 10 | |
| 55122 Mainz | |
| Germany | |
| ISIN: | DE000A3ENQ51 |
| WKN: | A3ENQ5 |
| Indices: | SDAX |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Vienna Stock Exchange |
| EQS News ID: | 1981761 |
| End of News | EQS News Service |
|
|
1981761 05.09.2024 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024e | ||
| Sales1 | 0,00 | 0,00 | 584,23 | 648,67 | 821,14 | 898,60 | 957,09 | |
| EBITDA1,2 | 0,00 | 0,00 | 131,94 | 164,10 | 219,73 | 239,00 | 257,55 | |
| EBITDA-Margin3 | 0,00 | 0,00 | 22,58 | 25,30 | 26,76 | 26,60 | 26,91 | |
| EBIT1,4 | 0,00 | 0,00 | 98,22 | 127,66 | 164,38 | 192,38 | 192,58 | |
| EBIT-Margin5 | 0,00 | 0,00 | 16,81 | 19,68 | 20,02 | 21,41 | 20,12 | |
| Net Profit (Loss)1 | 0,00 | 0,00 | 77,63 | 101,17 | 125,85 | 151,93 | 150,35 | |
| Net-Margin6 | 0,00 | 0,00 | 13,29 | 15,60 | 15,33 | 16,91 | 15,71 | |
| Cashflow1,7 | 0,00 | 0,00 | 104,40 | 132,21 | 182,12 | 181,65 | 225,33 | |
| Earnings per share8 | 0,00 | 0,00 | 0,51 | 0,67 | 0,83 | 1,01 | 0,99 | |
| Dividend per share8 | 0,00 | 0,00 | 0,00 | 0,00 | 0,12 | 0,15 | 0,18 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: Ernst & Young
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| Schott Pharma | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| A3ENQ5 | DE000A3ENQ51 | AG & Co. KGaA | 3.662,95 Mio € | 28.09.2023 | 9F2C268V+9J | |
| PE 2025e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| 22,52 | 28,92 | 0,78 | 28,68 | 4,78 | 16,26 | 3,83 |
|
Dividend '2022 in € |
Dividend '2023 in € |
Dividend '2024e in € |
Div.-Yield '2024e in % |
| 0,12 | 0,15 | 0,18 | 0,74% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 04.02.2025 | 13.02.2025 | 15.05.2025 | 12.08.2025 | 12.12.2024 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| -14,06% | -23,83% | -27,62% | -27,19% | -9,93% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.
Contact
